Cite

HARVARD Citation

    Staber, P. et al. (2021). Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. Leukemia & lymphoma. 62 (14), pp. 3440-3451. [Online]. 
  
Back to record